Surgical orchiectomy vs. medical castration in treatment of metastatic prostate cancer

A new study in JAMA Oncology has suggested that surgical orchiectomy may have lower risk for complications and side effects than medical castration with LHRH agonists (also known as GnRH agonists) like leuprolide acetate (Lupron) and others in treatment of men newly diagnosed with metastatic prostate cancer. This is a complex issue! … READ MORE …

Short-term outcomes after prostate cancer diagnosis and treatment in France

An article available in full on the Medscape web site provides an overview of short-term outcomes of > 43,000 men diagnosed with prostate cancer in France in 2009 and followed for 2 years based on data in the French national health insurance information system (SNIIRAM). You do need to register with Medscape to be able to read the article (but registration is free). … READ MORE …

Quality of life 12 to 32 months post-treatment among men in Norway

A recently reported study offers us data from a cohort of nearly 800 men in Norway, all diagnosed in 2004 with localized or locally advanced prostate cancer and then surveyed for quality of life in October 2006. … READ MORE …

Persistence of adverse effects for up to 10 years after treatment for localized prostate cancer

A new article just published by Taylor et al. in the Journal of Clinical Oncology provides detailed information about the persistence of clinically significant, long-term, prostate cancer-specific, treatment-related sexual and urinary adverse effects up to 10 years post-diagnosis. Coverage of this article also appears in a report on Reuters.com. … READ MORE …

Survey suggests high level of long-term side effects after treatment for prostate cancer

According to new data presented at the Frontiers in Cancer Prevention Research meeting ongoing this week in Boston, MA, some 70 percent of prostate cancer patients participating in a survey in Michigan reported long-term, treatment-related, adverse effects after first-line treatment with surgery or radiation therapy. … READ MORE …

Long-term QoL of men in the Scandinavian Prostate Cancer Group 4 clinical trial

In 1989 the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) started randomizing men with a clinically initiated diagnosis of localized prostate cancer to either watchful waiting or open radical prostatectomy as their primary treatment. A new paper has now addressed the long-term quality of life (QoL) of men in this study. … READ MORE …

Can we reduce adverse effects of ADT through cyclical estrogen therapy?

The adverse effects of androgen deprivation therapy (ADT) resulting from the use of surgical castration (orchiectomy) or medical castration (luteinizing hormone-releasing hormone [LHRH] agonists) are extensive, including sexual dysfunction, hot flashes, osteoporosis, and many others. … READ MORE …